Medirom Healthcare Technologies Stock Cash Per Share
| MRM Stock | USD 0.93 0.01 1.06% |
Medirom Healthcare Technologies fundamentals help investors to digest information that contributes to Medirom Healthcare's financial success or failures. It also enables traders to predict the movement of Medirom Stock. The fundamental analysis module provides a way to measure Medirom Healthcare's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Medirom Healthcare stock.
| Last Reported | Projected for Next Year | ||
| Cash Per Share | 23.79 | 22.60 |
Medirom | Cash Per Share |
Medirom Healthcare Technologies Company Cash Per Share Analysis
Medirom Healthcare's Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Current Medirom Healthcare Cash Per Share | 72.70 X |
Most of Medirom Healthcare's fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Medirom Healthcare Technologies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Medirom Cash Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for Medirom Healthcare is extremely important. It helps to project a fair market value of Medirom Stock properly, considering its historical fundamentals such as Cash Per Share. Since Medirom Healthcare's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Medirom Healthcare's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Medirom Healthcare's interrelated accounts and indicators.
Click cells to compare fundamentals
Medirom Cash Per Share Historical Pattern
Today, most investors in Medirom Healthcare Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Medirom Healthcare's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's cash per share growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Medirom Healthcare cash per share as a starting point in their analysis.
Medirom Healthcare Cash Per Share |
| Timeline |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
| Competition |
Medirom Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
In accordance with the recently published financial statements, Medirom Healthcare Technologies has a Cash Per Share of 72 times. This is much higher than that of the Health Care Providers & Services sector and notably higher than that of the Health Care industry. The cash per share for all United States stocks is notably lower than that of the firm.
Medirom Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Medirom Healthcare's direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Medirom Healthcare could also be used in its relative valuation, which is a method of valuing Medirom Healthcare by comparing valuation metrics of similar companies.Medirom Healthcare is currently under evaluation in cash per share category among its peers.
Medirom Healthcare Current Valuation Drivers
We derive many important indicators used in calculating different scores of Medirom Healthcare from analyzing Medirom Healthcare's financial statements. These drivers represent accounts that assess Medirom Healthcare's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Medirom Healthcare's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 6.0B | 3.4B | 3.2B | 4.2B | 4.8B | 5.8B | |
| Enterprise Value | 6.4B | 5.1B | 5.1B | 7.7B | 8.9B | 7.7B |
Medirom Fundamentals
| Return On Equity | 1.47 | ||||
| Return On Asset | -0.036 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | (0.02) % | ||||
| Current Valuation | 29.3 M | ||||
| Shares Outstanding | 7.9 M | ||||
| Shares Owned By Insiders | 40.37 % | ||||
| Number Of Shares Shorted | 59.24 K | ||||
| Price To Book | 13.24 X | ||||
| Price To Sales | 0 X | ||||
| Revenue | 6.83 B | ||||
| Gross Profit | 1.57 B | ||||
| EBITDA | 310.08 M | ||||
| Net Income | 115.05 M | ||||
| Cash And Equivalents | 354.95 M | ||||
| Cash Per Share | 72.70 X | ||||
| Total Debt | 3.65 B | ||||
| Current Ratio | 0.36 X | ||||
| Book Value Per Share | 43.19 X | ||||
| Cash Flow From Operations | (631.74 M) | ||||
| Short Ratio | 0.71 X | ||||
| Earnings Per Share | (0.15) X | ||||
| Number Of Employees | 390 | ||||
| Beta | 0.009 | ||||
| Market Capitalization | 7.33 M | ||||
| Total Asset | 6.85 B | ||||
| Retained Earnings | 80.28 M | ||||
| Working Capital | (1.8 B) | ||||
| Net Asset | 6.85 B |
About Medirom Healthcare Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Medirom Healthcare Technologies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Medirom Healthcare using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Medirom Healthcare Technologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Medirom Healthcare Piotroski F Score and Medirom Healthcare Altman Z Score analysis. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Medirom Healthcare. If investors know Medirom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Medirom Healthcare listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.582 | Earnings Share (0.15) | Revenue Per Share | Quarterly Revenue Growth (0.06) | Return On Assets |
The market value of Medirom Healthcare is measured differently than its book value, which is the value of Medirom that is recorded on the company's balance sheet. Investors also form their own opinion of Medirom Healthcare's value that differs from its market value or its book value, called intrinsic value, which is Medirom Healthcare's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Medirom Healthcare's market value can be influenced by many factors that don't directly affect Medirom Healthcare's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Medirom Healthcare's value and its price as these two are different measures arrived at by different means. Investors typically determine if Medirom Healthcare is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Medirom Healthcare's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.